Macupatide clinical trials
Also written LY3532226.
How each study uses macupatide is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the macupatide studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
8 studies that test it; most in 2023 (2)
| Year | Studies |
|---|---|
| 2021 | 1 |
| 2022 | 1 |
| 2023 | 2 |
| 2024 | 1 |
| 2025 | 1 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 8 · Other 0
Often tested with
Tested in the same studies.
Eloralintide (4) · Dulaglutide (1) · Mazdutide (1) · Naperiglipron (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 4
Studies that test macupatide.
- Mar 2027A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 DiabetesPhase 2 · Eli Lilly and Company
- Jun 2027A Study of Macupatide (LY3532226) in Participants With Obesity or Overweight Without Type 2 DiabetesPhase 1 · Eli Lilly and Company
- Sep 2027A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or OverweightPhase 2 · Eli Lilly and Company
- Sep 2027A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or OverweightPhase 2 · Eli Lilly and Company
Studies
Open first, then newest update. How each study uses macupatide is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 8
- A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or OverweightRecruitingPhase 2Eli Lilly and CompanyNCT07589608Written as Macupatide
- A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or OverweightRecruitingPhase 2Eli Lilly and CompanyNCT06143956Written as LY3532226
- A Study of Macupatide (LY3532226) in Participants With Obesity or Overweight Without Type 2 DiabetesNot yet recruitingPhase 1Eli Lilly and CompanyNCT07765511Written as Macupatide
- A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 DiabetesActive, not recruitingPhase 2Eli Lilly and CompanyNCT07215559Written as Macupatide
- A Study of LY3532226 in Participants With ObesityCompletedPhase 1Eli Lilly and CompanyNCT06557356Written as LY3532226
- A Study of LY3532226 in Participants With Type 2 Diabetes MellitusCompletedPhase 1Eli Lilly and CompanyNCT05407961Written as LY3532226
- A Study of LY3532226 in Participants With Type 1 Diabetes MellitusCompletedPhase 1Eli Lilly and CompanyNCT05887999Written as LY3532226
- A Study of LY3532226 in Healthy ParticipantsCompletedPhase 1Eli Lilly and CompanyNCT04923269Written as LY3532226
Codes
What other systems call macupatide · ClinicalTrials.gg INT018625
- UNII (FDA) YWF427CA5DMACUPATIDEOne source FDA
- NCI Thesaurus C213416MacupatideOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | YWF427CA5D | MACUPATIDE | One source FDA |
| NCI Thesaurus | C213416 | Macupatide | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.